![]() |
|
|
Vol. 302, Issue 2, 545-550, August 2002
1.2 Subunit
Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee
| |
Abstract |
|---|
|
|
|---|
Kv1.5 is the principal molecular component of IKur, an
atrial-specific K+ current in human myocytes that is
suppressed by activation of protein kinase C (PKC). We examined the
effect of phorbol 12-myristate 13-acetate (PMA), a direct activator of
PKC, on Kv1.5 current. Although PMA had minimal effect when Kv1.5 was
expressed alone, K+ currents derived from coexpression of
Kv
1.2 (but not another closely related
subunit, Kv
1.3) with
Kv1.5 were markedly reduced by PMA, associated with a small
depolarizing shift in the voltage dependence of channel activation.
Additional experiments with an inactive stereoisomer, 4
-PMA, and the
PKC inhibitor chelerythrine indicated that the effects of PMA were
mediated by PKC activation. Assembly of Kv1.5 in vivo with both
subunits was demonstrated, and all three K+ channel
proteins were substrates for phosphorylation by PKC. These results
demonstrate that coexpression of Kv
1.2 enhances the response of
Kv1.5 to PKC activation and that direct phosphorylation of
K+ channel subunits is a potential molecular basis for the
effect. Furthermore, they suggest that Kv
1.2 may be a component of
the IKur complex in human atrium.
| |
Introduction |
|---|
|
|
|---|
Atrial
fibrillation (AF) is the most common sustained cardiac arrhythmia in
the Western world (Prystowsky et al., 1996
; Pelosi and Morady, 2000
;
Chugh et al., 2001
; Go et al., 2001
) and remains a major cause of
stroke and death in the elderly in this country. Most antiarrhythmic
drugs used to treat AF block K+ channels as their
primary mechanism of action. However, the efficacy of these drugs has
been disappointing (Prystowsky et al., 1996
; Eckman et al., 1998
). In
addition, all currently available K+ channel
blockers can cause marked prolongation of ventricular repolarization
and the QT interval, predisposing patients to the development of the
polymorphic ventricular tachycardia Torsades de Pointes, syncope, and
sudden cardiac death (Roden, 1996
; Nattel, 1999
). In both atrium and
ventricle, late or phase 3 repolarization of the action potential is
mediated by noninactivating K+ currents or
delayed rectifiers (IK). Both rapidly
(IKr) and slowly (IKs)
activating components with distinct pharmacologic profiles have been
described (Nattel, 1999
). Substantial evidence indicates that both
cardiac and noncardiac drugs that cause Torsades de Pointes block
IKr as a common mechanism of action (Nattel,
1999
). Clearly, pharmacologic therapy directed specifically at atrial currents (rather than IKr, which resides in both
atrium and ventricle) would reduce toxicity and likely improve efficacy.
A delayed rectifier with ultra-rapid activation
(IKur) has been identified in atrial, but not
ventricular, human cardiac myocytes (Fedida et al., 1998
; Nattel et
al., 1999
). This K+ current is distinct, because
it is sensitive to block by low concentrations of
4-aminopyridine but resistant to tetraethylammonium, dendrotoxin, and charybdotoxin (Nattel et al., 1999
). Given its atrial
specificity, there is considerable interest in
IKur as a pharmacologic target to treat AF. Kv1.5
encodes a rapidly activating delayed rectifier that is also sensitive
to block by low micromolar concentrations of 4-aminopyridine but
insensitive to tetraethylammonium, dendrotoxin, and charybdotoxin.
These characteristics are very similar to those of human
IKur, suggesting that Kv1.5 forms the principal
molecular basis for the current (Paulmichl et al., 1991
; Snyders et
al., 1993
; Coetzee et al., 1999
). This concept is further supported by
the fact that exposure of human atrial cells to Kv1.5 antisense
oligonucleotides causes a major reduction in IKur
(Feng et al., 1997
).
Kv
subunits like Kv1.5 can coassemble as either homo- or
heterotetramers to form a functional channel (Coetzee et al., 1999
). Further diversity of K+ currents arises from
coassembly of auxiliary or accessory proteins, such as
subunits,
with Kv
subunits (Rhodes et al., 1995
; Shamotienko et al., 1997
;
Coleman et al., 1999
). Two
subunits cloned from human heart,
Kv
1.2 and Kv
1.3, represent splice variants from the same gene,
with identical carboxyl termini that mediate interaction with the
subunit and divergent amino termini. Multiple studies suggest that both
Kv
1.2 and Kv
1.3 can coassemble with Kv1.5 (Sewing et al., 1996
;
Wang et al., 1996
), as coexpression results in K+
currents with partial, fast inactivation, a hyperpolarizing shift in
the voltage dependence of activation, and slowing of deactivation compared with Kv1.5 alone (England et al., 1995a
,b
; Majumder et al.,
1995
). At present, it is not known whether
subunits coassemble with
Kv1.5 in vivo to form IKur.
A notable feature of IKur is its modulation by
adrenergic stimulation (Li et al., 1996
). Activation of protein kinase
A (PKA) causes an increase in K+ current
amplitude for IKur (Li et al., 1996
). We have
previously shown that coexpression of Kv
1.3, but not Kv
1.2, with
Kv1.5 results in a reproducible increase in K+
current in response to PKA stimulation (Kwak et al., 1999
), suggesting that
subunit coassembly with Kv1.5 is required to recapitulate the
complete IKur phenotype. Stimulation of
-adrenergic receptors causes suppression of
IKur in human atrial myocytes, an effect mediated
by PKC (Li et al., 1996
). To test the hypothesis that the response of
Kv1.5 to PKC activation also requires
subunit coassembly, we have
examined the effects of PKC activation on K+
currents derived from Kv1.5 in the absence and presence of
subunit
coexpression. Our results indicate that coassembly of Kv
1.2 in the
Kv1.5 complex enhances the response of the K+
current to PKC activation. Taken together with our previous findings, these results suggest that one or more
subunits may coassemble with
Kv1.5 to recapitulate the response of IKur to
adrenergic stimulation.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials and Antibodies.
Reagent grade chemicals and PMA
were obtained from Sigma-Aldrich (St. Louis, MO), and 4
-PMA
and chelerythrine were obtained from LC Laboratories (Woburn,
MA). Enzymes and buffers were from Roche Diagnostics
(Indianapolis, IN) and Promega (Madison, WI). The antibody directed
against the influenza hemagglutinin (HA) epitope (anti-HA) was
purchased from CRP Inc. (Princeton, NJ), the anti-FLAG M2 and
anti-FLAG horseradish peroxidase-conjugated antibodies were obtained
from Sigma-Aldrich, and a polyclonal antibody directed against the
amino terminus of Kv1.5 (anti-Kv1.5) was kindly provided by Dr. Mike
Tamkun (Colorado State University, Ft. Collins, CO). The source of
other reagents is specified below.
K+ Channel Expression.
DNA constructs of Kv1.5,
Kv
1.2, and Kv
1.3 (each in a modified pSP64T vector) (England et
al., 1995a
,b
) were linearized with EcoRI and cRNA
transcribed using the SP6 RNA polymerase (SP6 Cap-Scribe; Roche
Diagnostics). Defolliculated Xenopus laevis oocytes were prepared as described previously and injected with approximately 40 nl
of RNA (Kwak et al., 1999
). Kv1.5 cRNA was diluted using RNase-free
water so that currents for experimentation did not exceed 8 µA. This
was combined with an excess of undiluted
cRNA in ratios that
achieved maximal effect, as assessed by K+
current characteristics during electrophysiologic recordings (England
et al., 1995a
,b
; Uebele et al., 1996
). Use of animals was performed in
accordance with the Guide for the Care and Use of Laboratory Animals
from the National Institutes of Health.
1.2-HA and Kv
1.3-HA were constructed by fusing, in frame, three
copies of the HA epitope to the 3' end of the cDNA. The human Kv1.5
cDNA was inserted into p3XFLAG-CMV 7.1 expression vector
(Sigma-Aldrich), resulting in amino-terminal insertion of the FLAG
epitope. HEK 293 (human embryonic kidney) cells that were approximately
70 to 80% confluent were transiently transfected with Kv1.5-FLAG + Kv
1.2-HA or Kv
1.3-HA using LipofectAMINE Plus (Invitrogen,
Carlsbad, CA) according to the manufacturer's instructions. Cells were harvested 48 h later for immunoprecipitation experiments.
Electrophysiologic Recordings and Data Analysis.
Electrophysiologic recordings were performed 24 to 48 h following
injection of oocytes, using the two-microelectrode voltage-clamp technique as described previously (Kwak et al., 1999
). The holding potential was
80 mV, and the cycle time for all pulse protocols was
10 s or slower to allow full recovery from inactivation between pulses. To calculate cell membrane electrical capacitance, the capacitive transient was recorded during a small voltage step (
80 to
70 mV) during which K+ currents were not
activated. Integration of the leak-corrected transient yielded the
charge (Q) transferred during the voltage step
(V) from which capacitance (C) was calculated:
C = Q/V. All experiments were
conducted at room temperature (22 ± 2°C).
Immunoprecipitation of K+ Channel Subunits. Following transfection with K+ channel subunits, HEK 293 cells were harvested and lysed in 20 mM Tris (pH 7.5), 20 mM NaCl, 1 mM EDTA, 2 mM dithiothreitol, and protease inhibitors (complete mini; Roche Diagnostics). Cellular debris was removed by centrifugation at 13,000 rpm for 10 min at 4°C. Two milligrams of whole cell lysate were incubated with 4 µg of anti-HA or anti-FLAG antibody overnight at 4°C. Immunocomplexes were precipitated by the addition of 30 µl of packed protein A-Sepharose affinity resin. The resin was washed with lysis buffer, and proteins were eluted at 100°C in Laemmli sample buffer. Samples were size-fractionated on a denaturing polyacrylamide gel and transferred to nitrocellulose (Hybond-ECL; Amersham Biosciences, Piscataway, NJ) via semidry transfer. Membranes were blocked in phosphate-buffered saline containing 2% bovine serum albumin. To detect HA-tagged proteins, membranes were incubated with primary antibody (anti-HA, 1:8,000) in blocking solution. Horseradish peroxidase-conjugated secondary antibodies in phosphate-buffered saline allowed for subsequent detection of protein with the enhanced chemiluminescence system (Amersham Biosciences). To detect FLAG-tagged proteins, a horseradish peroxidase-conjugated anti-FLAG antibody was used (1:10,000).
Phosphorylation of K+ Channel Subunits.
cDNAs
for Kv
1.2-HA, Kv
1.3-HA, and Kv1.5 were amplified using the
polymerase chain reaction and subsequently ligated into pGEX2T-KG (Guan
and Dixon, 1991
) to create glutathione S-transferase fusion
proteins. The recombinant plasmids were sequenced to confirm that the
reading frames were not disrupted and that there were no errors arising
from the amplification. The plasmids were transformed into JM109
bacteria for growth and induction of expression with 1 mM
isopropyl-1-thio-
-D-galactopyranoside. The
bacteria were lysed by passing twice through a French press in the
presence of 100 mM Tris, pH 7.5, and 1 mM EDTA, and cellular debris was pelleted by centrifugation at 58,000g. The fusion protein
was purified with glutathione-agarose affinity resin and eluted with 10 mM glutathione. The glutathione S-transferase moiety was
cleaved from the channel subunit by incubation with four units of
thrombin protease at room temperature for 20 min (Guan and Dixon,
1991
). Ten micrograms of purified K+ channel
subunit were incubated at 30°C for 30 min in kinase reaction buffer
[50 mM Tris (pH 7.4), 10 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 100 µM ATP, and 2 µCi of
-[32P]ATP] in the absence or presence of 4 ng of the PKC catalytic subunit (Calbiochem, San Diego, CA). Following
electrophoretic separation and transfer to nitrocellulose,
phosphorylated proteins were visualized by autoradiography.
| |
Results |
|---|
|
|
|---|
The Role of Kv
1.2 in the Response to PKC Activation.
To
investigate the effects of PKC activation, K+
currents derived from expression of Kv1.5 alone were studied initially.
PKC was activated directly using the phorbol ester PMA. In Fig.
1A, K+ currents
elicited by depolarizing voltage steps are shown under control
conditions (left) and following exposure to PMA (right). Bath
superfusion of PMA had little effect on Kv1.5 current, as also
highlighted by the summary data in Fig. 3 (
9 ± 5% at +50 mV
after 30 min of PMA).
|
1.2 or Kv
1.3 can modify Kv1.5 currents. In
addition, their amino acid sequences contain multiple consensus sites
for phosphorylation by PKC (Kennelly and Krebs, 1991
-
subunit interaction in
the response to PKC, the effects of PMA were determined following coexpression of either Kv
1.2 or Kv
1.3 with Kv1.5. As previously reported, coexpression of either
subunit produced
K+ currents that demonstrated partial, fast
inactivation and slowed deactivation compared with Kv1.5 alone (Fig. 1,
B and C, left panels), with a negative shift in the voltage dependence
of channel activation (e.g., midpoint or
V1/2 of the activation curve was
9 ± 2 mV for Kv1.5 alone and
19 ± 3 mV for Kv1.5 + Kv
1.2). We have previously shown that coexpression of Kv
1.3 is
necessary for the PKA-mediated increase in Kv1.5 current (Kwak et al.,
1999
1.3 (
1 ± 2% after 30 min; Figs. 1B
and 3). On the other hand, the phorbol ester markedly reduced K+ current when Kv
1.2 was coexpressed with
Kv1.5 (
45 ± 8% after 30 min; Figs. 1C and 3). Thus,
coexpression of Kv
1.2, but not Kv
1.3, with Kv1.5 enhanced the
response of the channel to PMA.
The time course of the PMA effect is illustrated in Fig.
2. Because phorbol esters can cause a
concentration- and time-dependent reduction in cell membrane surface
area due to internalization, capacitance was also measured as in
indicator of cell membrane surface area, and data are shown as current
density (current normalized for capacitance). For a representative
group of cells, there was no significant change in capacitance over the
time course of experiments (
6-7 ± 2-3% after 30 min of PMA;
data not shown).
|
-PMA had
essentially no effect on K+ current derived from
Kv1.5 + Kv
1.2, as demonstrated in Fig. 3 (+4 ± 3% after 30 min of PMA).
If the effects of PMA are mediated by PKC activation, they should be
reduced or eliminated by inhibition of the kinase. Cells expressing
Kv1.5 + Kv
1.2 were preincubated with the PKC inhibitor chelerythrine
(20 µM) for 20 to 30 min (Herbert et al., 1990
14 ± 9% after 30 min). Taken together, these
findings indicate that the effects of PMA on K+
currents derived from Kv1.5 + Kv
1.2 are mediated by activation of
PKC.
|
Effect of PKC Activation on K+ Current Gating.
The
effect of PMA on the biophysical properties of Kv1.5 + Kv
1.2
currents was also examined. As illustrated in Fig.
4A, a small depolarizing shift in the
activation curve occurred with bath application of PMA (
19 ± 3 mV at baseline and
14 ± 3 mV following PMA; p < 0.001). Although this effect was statistically significant, it was
not sufficient to account for the reduction observed in
K+ current. There was no change in either the
extent of macroscopic K+ current inactivation
(ratio of steady state to peak current was 61 ± 5% at baseline
and 63 ± 5% following PMA) or the voltage dependence of this
process following PMA (V1/2 of the
inactivation curve was
31 ± 3 mV before and
32 ± 3 mV
after PMA; Fig. 4B). Of note, PMA did not alter the voltage dependence
of channel activation in cells expressing Kv1.5 alone
(V1/2 of the activation curve was
9 ± 2 mV at baseline and
9 ± 2 mV following PMA).
|
Kv
1.2 and Kv
1.3 Coassemble with Kv1.5.
Using the yeast
two-hybrid assay, Kv1.5 has been shown to bind Kv
1.2 and Kv
1.3 in
vitro (Wang et al., 1996
), and coexpression studies have also suggested
-
coassembly. To confirm that these
and
subunits
associate in vivo, reciprocal coimmunoprecipitation experiments were
performed. Using a Kv1.5 construct that was tagged with the FLAG
epitope and Kv
subunits tagged with the HA epitope, immunoprecipitation was performed using anti-FLAG and anti-HA antibodies following
-
coexpression. Following electrophoretic separation and transfer to nitrocellulose, Western blot analyses were
performed. When anti-FLAG is used as the precipitating antibody, a
doublet at ~75 and 85 kDa is detected (Fig.
5A, lanes 5 and 6), and this signal
comigrates with bands representing Kv1.5 in the absence of
precipitating antibody (Fig. 5A, lanes 2 and 3). Furthermore, Kv
1.2
and Kv
1.3 are also detected under these conditions (Fig. 5B, lanes 5 and 6), indicating that the
and
subunits are associated within
the cell. As well, immunoprecipitation with anti-HA results in
detection of the
subunits (Fig. 5B, lanes 8 and 9) as well as Kv1.5
(Fig. 5A, lanes 8 and 9). No signals were detected in nontransfected
cell lysate subjected to immunoprecipitation by either anti-HA or
anti-FLAG (Fig. 5, A and B, lanes 1, 4, and 7). Taken together, these
data indicate that Kv1.5 is associated with the Kv
subunits in vivo.
|
Phosphorylation of K+ Channel Subunits.
The
response to PKC activation suggests that direct phosphorylation of the
and/or
subunit may underlie the reduction in current. The amino
acid sequences of Kv1.5 and Kv
1.2 contain numerous consensus
sequence sites for phosphorylation by PKC. Therefore, in vitro
phosphorylation studies were carried out to determine whether the
subunits are substrates for PKC. Ten micrograms of bacterially
expressed, purified Kv
1.2 protein were incubated with ATP in the
presence or absence of the catalytic subunit of PKC. As shown in Fig.
6A (lanes 1 and 2), a ~46 kDa protein
was phosphorylated in the presence of the kinase. Subsequent Western analysis with an antibody directed against the HA epitope was performed
on the same membrane, confirming that the phosphorylation signal
comigrated with Kv
1.2 and that there was equal loading of protein
(lanes 3 and 4). A similar approach was used to determine whether Kv1.5
is a substrate for PKC. A ~72 kDa protein is specifically modified in
the presence of the kinase (Fig. 6B, lanes 1 and 2), and this signal
comigrated with a protein that was detected by an anti-Kv1.5 antibody
(lanes 3 and 4). Note that Kv1.5 migrated as a single band. This is
likely due to lack of post-translational modification of mammalian
proteins in bacteria. Thus, both channel subunits are substrates for
PKC in vitro.
|
1.2 that
are present in the conserved carboxyl terminus shared by the
subunits. Consequently, we also examined whether Kv
1.3 could be
modified by PKC. Like Kv
1.2, Kv
1.3 is a substrate for PKC
phosphorylation in vitro (Fig. 6C, lanes 1 and 2).
| |
Discussion |
|---|
|
|
|---|
Our results demonstrate that coexpression of the Kv
1.2 subunit
with Kv1.5 enhances the response of the channel to PKC activation. The
resultant suppression of K+ current resembles
that seen for IKur (Li et al., 1996
), an
atrial-specific K+ current in human myocytes for
which Kv1.5 is known to be the principal molecular correlate (Paulmichl
et al., 1991
; Snyders et al., 1993
; Coetzee et al., 1999
).
IKur is one of multiple cardiovascular K+ currents inhibited by activation of the
-adrenergic receptors and PKC. The resulting prolongation in action
potential duration will increase atrial refractoriness and thus could
potentially help protect against the development of atrial fibrillation
(Li et al., 1996
; Nattel et al., 1999
). Although the
K+ channel subunit composition of
IKur is currently unknown, our results indicate
that Kv1.5 can coassemble with both
subunits studied in vivo, and
they suggest a requirement for Kv
1.2 to recapitulate the response of
IKur to PKC activation. It was recently shown
that Kv
1.2 is associated with Kv1.5 in the formation of Kv channel
complexes in vascular smooth muscle (Thorneloe et al., 2001
) and human
atrium (Kuryshev et al., 2001
), providing additional supporting
evidence that the two K+ channel subunits might
coassemble in the IKur complex.
Previous studies using mouse (Attali et al., 1993
), rat (Timpe and
Fantl, 1994
), and canine (Vogalis et al., 1995
) homologs of Kv1.5 have
suggested that the
subunit is sensitive to activation of PKC.
However, in some cases, K+ current suppression
was variable (Timpe and Fantl, 1994
). In addition, for some studies, a
reduction in K+ current due to significant
internalization of plasma membrane cannot be ruled out given the
concentration of phorbol ester used (Vasilets et al., 1990
) and the
fact that capacitance, and thus K+ current
density, was not monitored (Attali et al., 1993
; Vogalis et al., 1995
).
The response of the human Kv1.5 isoform to PKC activation has not been
examined previously.
Our experimental results indicate that all three
K+ channel subunits under study are substrates
for phosphorylation by PKC. Consensus sequences for PKC phosphorylation
include (R/K1-3, X2-0)-S/T-(X2-0,
R/K1-3) > S/T-(X2-0, R/K1-3)
(R/K1-3, X2-0)-S/T
(Kennelly and Krebs, 1991
; Pinna and Ruzzene, 1996
). Twenty potential
PKC phosphorylation sites are present within the intracellular regions
of the Kv1.5 amino acid sequence. For the Kv
subunits, 10 consensus
sites for PKC phosphorylation are present in the unique amino terminus of Kv
1.2, whereas there are 27 sites present in the shared carboxyl terminus. Given the multiplicity of potential unique sites within Kv
1.2, we did not attempt to identify the site(s) responsible.
We have previously shown that coexpression of Kv
1.3 with Kv1.5 is
required for the PKA-mediated increase in K+
current (Kwak et al., 1999
). IKur is similarly
modulated by
-adrenergic stimulation and activation of PKA. Taken
together with the results of our present study, these data suggest that
coassembly of more than one
subunit with Kv1.5 may be required to
recapitulate the complete phenotype of IKur and
its modulation by adrenergic stimulation. The possibility that more
than one Kv
subunit might be required is not surprising, given that
immunoprecipitation experiments in brain have revealed that often two
subunits can be found coassembled with a single Kv1
subunit (Xu
and Li, 1998
; Coleman et al., 1999
). However, it is stressed that Kv1.5 + Kv
1.2 + Kv
1.3 cannot by itself represent the cell molecular
components of IKur due to the fast inactivating
phenotype of the recombinant K+ currents, which
is not a property of IKur.
In summary, we have shown that coassembly of Kv
1.2 with Kv1.5
enhances response of the channel to PKC activation, with a reduction in
K+ current. These data lend further support to
the concept that the Kv1.5
subunit alone may not form the sole
molecular basis of IKur but that additional
K+ channel subunits are required.
| |
Footnotes |
|---|
Accepted for publication April 25, 2002.
Received for publication January 18, 2002.
This work was supported by grants from the National Institutes of Health (R01 HL47599) and the American Heart Association (Southeast Affiliate).
DOI: 10.1124/jpet.102.033357
Address correspondence to: Dr. Katherine T. Murray, Department of Pharmacology, Room 559, Preston Research Building, Vanderbilt University School of Medicine, 23rd Avenue South at Pierce Avenue, Nashville, TN 37232-6602. E-mail: kathy.murray{at}mcmail.vanderbilt.edu
| |
Abbreviations |
|---|
AF, atrial fibrillation; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PKA, cAMP-dependent protein kinase (protein kinase A); HA, hemagglutinin.
| |
References |
|---|
|
|
|---|
2.1 subunits.
J Biol Chem
271:
2406-2412This article has been cited by other articles:
![]() |
C. V. Remillard, D. D. Tigno, O. Platoshyn, E. D. Burg, E. E. Brevnova, D. Conger, A. Nicholson, B. K. Rana, R. N. Channick, L. J. Rubin, et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1837 - C1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Maguy, T. E. Hebert, and S. Nattel Involvement of lipid rafts and caveolae in cardiac ion channel function Cardiovasc Res, March 1, 2006; 69(4): 798 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, W. Zhang, K. Wu, A.-B. Wimmer, B. Gut, G. Wendt-Nordahl, S. Kathofer, V. A.W. Kreye, H. A. Katus, W. Schoels, et al. Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein Cardiovasc Res, July 1, 2003; 59(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||